AVGR - Avinger, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3095
-0.0105 (-3.28%)
At close: 4:00PM EDT

0.3050 -0.00 (-1.45%)
After hours: 5:15PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3200
Open0.3131
Bid0.3050 x 1300
Ask0.3092 x 1800
Day's Range0.3000 - 0.3175
52 Week Range0.2410 - 2.9900
Volume2,340,530
Avg. Volume4,089,206
Market Cap15.889M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-2.4310
Earnings DateMay 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Avinger Announces Exercise and Closing of Underwriter's Over-Allotment Offering

    REDWOOD CITY, CA / ACCESSWIRE / July 9, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriters of its previously announced underwritten public offering have exercised, in full, their option to purchase an additional 3,000,000 shares of its common stock at a price of $0.27 per share. The shares were offered pursuant to a registration statement on Form S-1 (File No. 333-239177) previously filed with the Securities and Exchange Commission ("SEC"), and a related registration statement on Form S-1 (File No. 333-239398) filed pursuant to rule 462(b) of the Securities Act of 1933, which registration statements were declared effective by the SEC.

  • 2 Beaten-Up Penny Stocks That Are Set for a Rebound
    TipRanks

    2 Beaten-Up Penny Stocks That Are Set for a Rebound

    With the outbreak of the coronavirus, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among investors, others view market volatility as a unique buying opportunity.Opportunity is the key word – and sometimes the hardest thing for investors to see. To find names that can deliver solid returns and now come with a bargain price tag, investors will often turn to penny stocks, or those trading for less than $5 per share.Sure, there could be a very good reason these tickers are so affordable, but should there be even minor share price appreciation, massive percentage gains could materialize, along with hefty profits for investors.So, how are investors supposed to determine which names have what it takes to make a comeback? Follow the pros.Using TipRanks’ database, we were able to pinpoint two promising penny stocks, according to the analyst community. Although each has fallen below $3, the Buy-rated tickers appear poised to take off on an upward trajectory, boasting colossal upside potential.Xeris Pharmaceuticals (XERS)Based on its innovative technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, Xeris Pharmaceuticals provides solutions that simplify the process of administering important therapies. Even though its public offering prompted a serious sell-off on June 25, with the one-day loss coming in at 49%, the new $2.59 share price could allow investors to get in on the action before XERS blasts off.Representing Piper Sandler, analyst David Amsellem believes that the Street is underestimating XERS. Pointing to the results from its Phase 2 proof-of-concept study evaluating XP-3924, its liquid-stable, ready-to-use (RTU) coformulation of pramlintide and insulin in adult patients with type 1 diabetes, the analyst is optimistic about the candidate’s prospects going forward.The trial was designed as a randomized, open-label, 3-arm, cross-over study enrolling 18 adult participants, who were randomized to receive subcutaneous injections (SC) of XP-3924, regular insulin or co-administration of Symlin and insulin. It should be noted that Symlin is AstraZeneca’s product that needs to be injected separately from insulin, while Xeris' asset is given as a single injection.Importantly, post-prandial treatment with XP-3924 resulted in a 62% decrease in hyperglycemia compared to treatment with insulin alone. Adding to the good news, Amsellem highlights that glycemic control associated with XP-3924 was in line with that of the co-administration of pramlintide-insulin, and that glucose variability, or the variation of all plasma glucose levels across the six-hour monitoring period, was lower in patients treated with XP-3924 versus insulin alone and the co-administration of insulin with Symlin.“We do not believe that meaningful value is being ascribed to this opportunity (or other pipeline shots-on-goal for that matter), given our bullish view of the opportunity for Gvoke in severe hypoglycemia rescue (i.e., peak U.S. sales of $250 million-plus are realistic),” Amsellem commented.Looking ahead, Amsellem expects XERS to seek out a development partner, with management indicating “it could play a role in pramlintide-insulin commercialization with a partner given that the company already calls on endocrinologists in its support of Gvoke.” The analyst added, “As an aside, management also suggested that it would seek a partner for its injectable diazepam product for seizure clusters, though this is a relatively inexpensive development program focused on a concentrated prescriber audience, so in that vein, keeping full rights here would not be out of the question.”To this end, Amsellem rates XERS an Overweight (i.e. Buy) along with an $11 price target. This target implies shares could climb 326% higher in the next year. (To watch Amsellem’s track record, click here) Do other analysts agree with Amsellem? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $12.50, the average price target puts the potential twelve-month gain at 373%. (See XERS stock analysis on TipRanks)Avinger (AVGR)Avinger is a medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD).AVGR also tumbled recently on account of a $5.4 million public offering. Currently going for only $0.29 apiece, one member of the Street believes that now is the right time to snap up shares.Aegis Capital’s Nathan Weinstein notes that its recent capital raise via equity financing, its $2.3 million PPP loan and cash and equivalents of $9.9 million as of March 31, as well as its efforts to trim operating costs “have helped strengthen the company's balance sheet and financial runway.”Weinstein doesn’t dispute the fact that the current operating environment presents significant challenges including a pull-back in sales thanks to the pandemic, and a move to utilize virtual sales and marketing tools. That being said, AVGR’s clinical representatives continue to operate on customer sites when it’s possible.Expounding on this, the analyst stated, “A lack of clarity regarding a ‘return to normalcy’ pervades markets broadly, and PAD procedures are no exception. With that said, our current outlook calls for a gradual return to normalcy in patient volumes and customer ordering activity as we move forward through the calendar.”On top of this, there are several key catalysts on the horizon, in Weinstein’s opinion. These include the 510(k) submission for the Ocelaris image-guided CTO crossing catheter this quarter, the 510(k) submission for the L300 imaging console in 2H:20 and the completion of the INSIGHT IDE clinical study, which was designed to assess the safety and efficacy of Pantheris as a treatment for in-stent restenosis. Should the results be positive, they could support label expansion for Pantheris.“While we think each of these on their own are important, when we step-back and view the overall portfolio being completely refreshed, we believe the salesforce will be well-positioned to capitalize on the large PAD-treatment opportunity, especially when case volumes return,” Weinstein commented.In line with Weinstein’s optimistic take, he reiterates a Buy recommendation on AVGR. His $1.40 price target implies a twelve-month gain of 368% from current levels. (To watch Weinstein’s track record, click here) AVGR has stayed relatively under-the-radar so far, with its Moderate Buy consensus rating breaking down into 1 Buy and 1 Hold. Additionally, the $1.40 average price target matches Weinstein’s. (See Avinger stock-price forecast on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • ACCESSWIRE

    Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ: AVGR)

    NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR) About Avinger Inc. Avinger is a commercial-stage ...

  • ACCESSWIRE

    Avinger Closes $5.4 Million Underwritten Public Offering of Common Stock

    REDWOOD CITY, CA / ACCESSWIRE / June 26, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 20,000,000 shares of its common stock at a price of $0.27 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover over-allotments, if any. The shares were offered pursuant to a registration statement on Form S-1 (File No. 333-239177) previously filed with the Securities and Exchange Commission (SEC), and a related registration statement on Form S-1 (File No. 333-239398) filed pursuant to rule 462(b) of the Securities Act of 1933, which registration statements were declared effective by the SEC.

  • ACCESSWIRE

    Avinger Prices $5.4 Million Underwritten Public Offering of Common Stock

    REDWOOD CITY, CA / ACCESSWIRE / June 23, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be $5.4 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 20 million shares of the Company's common stock at a price of $0.27 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.

  • Rising P/E: An Overlooked Trick to Pick 5 Winning Stocks
    Zacks

    Rising P/E: An Overlooked Trick to Pick 5 Winning Stocks

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • Hedge Funds Are Warming Up To Avinger Inc (AVGR)
    Insider Monkey

    Hedge Funds Are Warming Up To Avinger Inc (AVGR)

    In this article we will take a look at whether hedge funds think Avinger Inc (NASDAQ:AVGR) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]

  • Avinger (AVGR) Upgraded to Strong Buy: Here's Why
    Zacks

    Avinger (AVGR) Upgraded to Strong Buy: Here's Why

    Avinger (AVGR) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Thomson Reuters StreetEvents

    Edited Transcript of AVGR earnings conference call or presentation 13-May-20 8:30pm GMT

    Q1 2020 Avinger Inc Earnings Call

  • ACCESSWIRE

    Avinger Announces 510(k) Filing of Ocelaris Next Generation Image-guided CTO Crossing System

    REDWOOD CITY, CA / ACCESSWIRE / May 20, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the Company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for pre-marketing clearance of Ocelaris, a next generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform. Ocelaris is a product line extension of Avinger's Ocelot family of image-guided CTO crossing catheters. Its design elements include an upgrade of the image capture rate to provide high definition, real-time intravascular imaging similar to the company's Pantheris image-guided atherectomy system and a user-controlled deflectable tip designed to assist in steerability within the lumen.

  • ACCESSWIRE

    Avinger Reports First Quarter 2020 Financial Results

    23% Year-Over-Year Revenue Growth Total Pantheris Revenue Increases 75% REDWOOD CITY, CA / ACCESSWIRE / May 13, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the ...

  • ACCESSWIRE

    Avinger to Announce First Quarter 2020 Results on May 13, 2020

    REDWOOD CITY, CA / ACCESSWIRE / May 7, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis ...

  • ACCESSWIRE

    Avinger Closes $3.15 Million Equity Offering

    REDWOOD CITY, CA / ACCESSWIRE / April 30, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 12,600,000 shares of its common stock at a price of $0.25 per share, for total gross proceeds of approximately $3.15 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover over-allotments, if any. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC).

  • ACCESSWIRE

    Avinger Prices $3.15 Million Underwritten Public Offering of Common Stock

    REDWOOD CITY, CA / ACCESSWIRE / April 27, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.15 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 12.6 million shares of the Company's common stock at a price of $0.25 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.

  • ACCESSWIRE

    Avinger Reports Preliminary First Quarter 2020 Revenue Results

    REDWOOD CITY, CA / ACCESSWIRE / April 15, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported preliminary results for the first quarter ended March 31, 2020. Revenue in the first quarter of 2020 is expected to be approximately $2.25 million, an increase of 22% over the first quarter of 2019, representing the company's third consecutive quarter with greater than 20% year-over-year revenue growth. Avinger launched 11 new Lumivascular sites during the first quarter in high volume areas, such as Arizona, Michigan, and Louisiana, which also contributed to revenue growth for the quarter.

  • Thomson Reuters StreetEvents

    Edited Transcript of AVGR earnings conference call or presentation 5-Mar-20 9:30pm GMT

    Q4 2019 Avinger Inc Earnings Call

  • ACCESSWIRE

    Avinger Reports Fourth Quarter 2019 Financial Results

    26% Year-Over-Year Fourth Quarter Revenue Growth Total Pantheris Revenue Increases 69% REDWOOD CITY, CA / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company ...

  • ACCESSWIRE

    Avinger, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (AVGR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 5, 2020 at 4:30 PM Eastern Time. ...

  • ACCESSWIRE

    Avinger to Announce Fourth Quarter 2019 Financial Results on March 5, 2020

    REDWOOD CITY, CA / ACCESSWIRE / February 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...

  • ACCESSWIRE

    Avinger Announces Publication of SCAN Clinical Study in Peer-Reviewed Journal

    REDWOOD CITY, CA / ACCESSWIRE / February 25, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the results of its SCAN clinical study have been published in the peer-reviewed journal BMC Medical Imaging. SCAN is a prospective, non-inferiority, post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. Study results showed that OCT imaging with Avinger's Pantheris system demonstrated statistical superiority or equivalence to IVUS on all parameters evaluated.

  • ACCESSWIRE

    Avinger's Pantheris Featured in Live Case Transmission at LINC 2020

    REDWOOD, CA / ACCESSWIRE / February 4, 2020 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), announced today that its Pantheris atherectomy system was featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020, a leading global forum for new methods in the field of vascular medicine held from January 28 through January 31 in Leipzig, Germany. Dr. Arne Schwindt and Dr. Angeliki Argyriou, vascular surgeons from St. Franziskus Hospital in Münster, Germany, performed the live endovascular procedure using Pantheris during a session entitled, "OCT-guided atherectomy of popliteal stent ISR followed by DCB." The patient for the live case presented with claudication and rest pain in the right leg, stemming from blockages within stents placed in a popliteal vein graft.

  • ACCESSWIRE

    Avinger Closes $4.5 Million Equity Offering

    REDWOOD CITY, CA / ACCESSWIRE / January 31, 2020 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 6,428,572 shares of its common stock at a price of $0.70 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The shares were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov.

  • ACCESSWIRE

    Avinger Announces the Passing of Director Donald A. Lucas

    REDWOOD CITY, CA / ACCESSWIRE / January 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...

  • ACCESSWIRE

    Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock

    REDWOOD CITY, CA / ACCESSWIRE / January 28, 2020 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 6,428,572 shares of the Company's common stock at a price of $0.70 per share. The Company intends to use the net proceeds from this offering to fund working capital, payment of interest on debt and general corporate purposes, which may include research and development of the Company's Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures.

  • ACCESSWIRE

    Avinger Enrolls First Patient in IMAGE-BTK Clinical Study Evaluating Safety and Efficacy Endpoints for Pantheris SV

    Post-Market Study Intended to Support Commercial Expansion of Small Vessel Image-Guided Atherectomy Device REDWOOD CITY, CA / ACCESSWIRE / January 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage ...